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OBJECTIVES: We investigated four components of the Wnt signaling pathway in medulloblastomas.
Medulloblastoma is the most common type of malignant pediatric brain tumor, and the Wnt signaling
pathway has been shown to be activated in this type of tumor.
METHODS: Sixty-one medulloblastoma cases were analyzed for b-catenin gene (CTNNB1) mutations, b-catenin
protein expression via immunostaining and Wnt signaling pathway-related gene expression. All data were
correlated with histological subtypes and patient clinical information.
RESULTS: CTNNB1 sequencing analysis revealed that 11 out of 61 medulloblastomas harbored missense
mutations in residues 32, 33, 34 and 37, which are located in exon 3. These mutations alter the glycogen
synthase kinase-3b phosphorylation sites, which participate in b-catenin degradation. No significant differences
were observed between mutation status and histological medulloblastoma type, patient age and overall or
progression-free survival times. Nuclear b-catenin accumulation, which was observed in 27.9% of the cases, was
not associated with the histological type, CTNNB1 mutation status or tumor cell dissemination. The relative
expression levels of genes that code for proteins involved in the Wnt signaling pathway (CTNNB1, APC, AXIN1
and WNT1) were also analyzed, but no significant correlations were found. In addition, large-cell variant
medulloblastomas presented lower relative CTNNB1 expression as compared to the other tumor variants.
CONCLUSIONS: A small subset of medulloblastomas carry CTNNB1 mutations with consequent nuclear
accumulation of b-catenin. The Wnt signaling pathway plays a role in classic, desmoplastic and extensive
nodularity medulloblastoma variants but not in large-cell medulloblastomas.
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& INTRODUCTION
Medulloblastomas are malignant neuroepithelial tumors
of the cerebellum and the most frequent pediatric primary
malignant intracranial neoplasm. They exhibit a tendency to
metastasize via cerebrospinal fluid (CSF) pathways (1,2).
The 2007 World Health Organization (WHO) classification
defines five histological subtypes of medulloblastoma:
classic, desmoplastic/nodular, extensively nodular, ana-
plastic and large-cell (3). Medulloblastomas are high-grade
embryonal tumors (WHO grade IV), and the deregulation of
various signaling pathways, such as the Shh, Notch and
Wnt pathways, involved in the normal development of the
cerebellum have been described as being involved in their
progression (4). Many authors have combined data from
clinical, pathologic and molecular analyses to identify four
to six distinct medulloblastoma variants (5-8), although the
current consensus is that there are only four core molecular
subgroups of medulloblastomas (9,10). Furthermore, a
subset of medulloblastomas associated with Wnt signaling
pathway activation has been associated with classical
histology and good prognosis (11). Wnt proteins, a group
of secreted proteins, regulate the cytoplasmic levels of b-
catenin, a component of the adherens junctions of mamma-
lian epithelial cells that, through a-catenin, link cadherin
cell-surface adhesion molecules to the actin cytoskeleton
(12). Adenomatous polyposis coli (APC) protein and
AXIN1, in a complex with glycogen synthase kinase-3b
(GSK3b), prevent b-catenin from entering the nucleus (13).
GSK3b phosphorylates b-catenin and thereby targets it for
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recognition by ubiquitination and consequent degradation
(14-16). In contrast, mutations in exon 3 of the b-catenin
gene (CTNNB1) in codons that code for phosphorylation
sites confer resistance to phosphorylation and guide the
translocation of b-catenin to the nucleus, where it acts as a
co-activator of the Tcf/Lef family of DNA-binding proteins
and leads to the upregulation of target genes (17-21).
A systematic analysis of a series of 61 sporadic medullo-
blastoma cases was performed to correlate histological
subtype and clinical data. b-catenin protein expression
analysis and mutational analysis of CTNNB1 was first
conducted, and a subsequent gene expression analysis of
the Wnt pathway components was performed.
& METHODS
Tumor samples, DNA and RNA extraction
The casuistic samples consisted of 61 medulloblastoma
patients who received surgeries from the neurosurgery
group of the Department of Neurology, Hospital das
Clı´nicas, School of Medicine, University of Sa˜o Paulo.
Forty-one samples were collected during resection and
were immediately snap-frozen and stored in liquid nitrogen
for DNA and RNA extraction. The tissue samples were
classified according to the morphology of the tumoral area
of higher degree of malignancy following the WHO
classification (3). Patients up to 18 years of age were
considered pediatric cases. Patient data concerning tumor
cell spread in cerebrospinal fluid (CSF), tumor localization,
degree of resection, as well as the overall and progression-
free survival time were analyzed. Tumor DNA was
extracted from all samples using the standard phenol/
chloroform method. Total RNA was extracted from each
sample using an RNeasy Mini Kit (Qiagen, Hilden,
Germany). The evaluation of RNA quantification and
purification was carried out by measuring the absorbance
at 260 and 280 nm. A260/280 ratios in the range of 1.8-2.0
were considered satisfactory for purity standards.
Denaturing agarose gel electrophoresis was used to assess
the quality of the samples. This study received the approval
of the local Ethical Committee of the Hospital das Clı´nicas
da Faculdade de Medicina da Universidade de Sa˜o Paulo.
Informed consent was obtained from all patients or their
legal guardians.
cDNA synthesis
A conventional reverse transcription reaction was per-
formed to yield single-stranded cDNA from 1 mg of total
RNA that was previously treated with one unit of DNase I
(FPLC-pure, GE Healthcare, Piscataway, NJ). The reaction
used random and oligo(dT) primers (Invitrogen, Carlsbad,
CA) for extension, RNase inhibitor (RNase OUT, Invitrogen)
and SuperScript III reverse transcriptase, according to the
manufacturer’s recommended protocol (Invitrogen). The
resulting cDNA was then treated with one unit of RNase H
(GE Healthcare) and diluted with TE buffer. A pooled
normal cerebellum total RNA sample was obtained from a
cerebellum pool of 24 males and females (age 16-70 years)
(Clontech, Mountain View, CA).
b-catenin immunohistochemical staining
For the immunohistochemistry (IHC) analysis, 5-mm
sections were deparaffinized and subjected to pressure
cooking epitope retrieval by steaming for 4 minutes, as
measured from the initiation of boiling in a citrate buffer
(10 mM, pH 6.0) (22). Anti-b-catenin mouse monoclonal
antibody (BD Transduction Laboratories, San Jose, CA) was
diluted (1:400) in buffer consisting of 1% albumin, 0.1%NaN3
and PBS. The primary antibodywas incubated overnight at 4
˚
C and then detected following incubation with a biotinylated
anti-mouse secondary antibody (Dako, Carpinteria, CA)
followed by a biotin-streptavidin peroxidase complex
(StreptABC Complex/HRP Kit, Dakocytomation, Glostrup,
Denmark) (23). Colon cancer tissue was used as a positive
control. The sections were then counterstained with Harris
hematoxylin, and a semi-quantitative analysis was per-
formed by two independent observers (RS and SKNM). The
localization of b-catenin was considered nuclear when, in
addition to a cytoplasmic/membrane reaction, more than
10% of tumor cell nuclei were positively stained.
Gene expression analysis
The relative expression levels of the Wnt pathway genes
were determined using quantitative real-time PCR (QT-PCR).
The following primers and fluorescence-labeled probes
were purchased from Applied Biosystems (Foster City, CA):
CTNNB1 (Hs00991820_g1), AXIN1 (Hs00394718_m1), APC
(Hs01568269_m1) andWNT1 (Hs01011249_g1). These desired
primers and probe sequences were obtained from references
in the NCBI dbSNP database. GUSB andHPRT1 were used as
endogenous controls. All samples and controls were tested in
duplicate. The PCR mixtures (10 ml) contained 3 ml of cDNA,
1 ml of primer and probe and 6 ml of TaqMan Universal
MasterMix (Applied Biosystems). PCR reactions were carried
out in an ABI Prism 7500 real-time thermal cycler with ‘‘FAM
no quencher’’ selected as the detector with the following
program: 50 C˚ for 5 min, followed by polymerase activation
at 95 C˚ for 10 min and a second step of 40 cycles at 95 C˚ for
15 s and 60 C˚ for 1 min. Values were normalized relative to
the internal housekeeping controls. The equation 2-DDCt was
applied to calculate the relative expression of CTNNB1,
AXIN1, APC and WNT1 in tumor samples versus the non-
neoplastic cerebellum pool, where DCt = target gene Ct – the
geometric mean of GUSB and HPRT1 Ct and DDCt = DCt
tumor -DCt cerebellum (24). The values of gene expression for
the normal cerebellum pool were set to 1. Gene expression
values above the median were considered overexpression for
the purposes of this analysis.
Statistical analysis
The statistical analyses of the relative gene expression
levels according to histological classification were per-
formed using the Kruskal-Wallis test. The Dunn multiple
comparison post-test was applied to compare the differ-
ences between medulloblastoma groups. A bivariate analy-
sis that measured the strengths of association between two
genes was performed using Spearman’s Rho correlation
method. Associations among the categorical variables were
tested using the x2 test. In cases where at least one of the
expected frequencies was below 5, Fisher’s exact test was
applied. Overall survival was calculated as the interval
between the date of initial diagnosis and the date of death or
the last follow-up, and progression-free survival was
measured from the date of initial diagnosis to the date of
first recurrence (the return of disease or the signs and
symptoms of disease after a period of improvement). The
Log rank test was used for univariate analysis to estimate
the differences in survival time for variables, according to
Molecular analysis of medulloblastomas
Silva R et al.
CLINICS 2013;68(2):167-172
168
the Kaplan-Meier method. Calculations were performed
using SPSS software, version 15.0 (Chicago, IL), and STATA,
version 7 (STATA Corp., College Station, TX). Values of
p,0.05 were considered statistically significant for all
analyses (including the Dunnmultiple comparison post-test).
& RESULTS
A total of 61 cases of medulloblastomas were available for
analysis, consisting of 38 pediatric cases (mean age 7.6
years) and 23 adult cases (mean age 30.8 years). There were
25 females and 36 males. Tumors with midline localization
were more frequent in patients under 18 years of age, with
89.5% of pediatric cases exhibiting midline localization
versus 56.5% of adult cases (p=0.005). Forty-four cases were
of the classic type (72.1%), 10 were large-cell (16.4%), four
were desmoplastic (6.6%) and three demonstrated extensive
nodularity (4.9%), according to the WHO histological
classification. Medulloblastomas with extensive nodularity
and desmoplastic cases were grouped for statistical ana-
lyses. Table 1 presents information concerning the mean age
at diagnosis, tumor cell dissemination to the CSF and
median overall and progression-free survival time for the
three groups according to histological classification. Large-
cell type medulloblastomas prevailed among younger
patients, who presented lower overall and progression-free
survival times as compared to patients with other medullo-
blastoma variants (p= 0.002 and p= 0.004, respectively).
Nuclear staining of b-catenin was identified in 17 out of
61 (27.9%) medulloblastomas (13 classic, one desmoplastic
and three large-cell cases) (Figure 1). There was no
association between b-catenin nuclear positivity and histo-
logical type (Table 1), age or gender. Cytoplasmic b-catenin
staining was detected in all cases.
Direct sequence analysis of the PCR amplification
products revealed heterozygous missense mutations of
CTNNB1 exon 3 in 11 out of 61 (18.0%) medulloblastomas.
Three were detected at codon 32 (GAC.AAC (two cases)
and GAC.TAC (one case)), as well as seven at codon 33
(TCT.TAT (five cases) and TCT.TGT (two cases)) and one
at codon 34 (GGA.AGA (one case)). The detected CTNNB1
mutations had no statistically significant relationship to any
specific histological type (eight classic, two large-cell and
one desmoplastic case) (Table 1) or age range (eight
pediatric and three adult cases). Among the 11 tumors
harboring CTNNB1 mutations, eight cases presented
nuclear b-catenin staining, five of which were the classic
type, one was desmoplastic and two were of the large-cell
Table 1 - Data from all analyzed patients, including age at diagnosis, tumor cell spread, overall and progression-free
survival and b-catenin immunohistochemistry results.
Histological classification
Classic Desmoplastic/extensive nodularity Large-cell p-value
Age at diagnosis (years) 17.5¡12.9 18.4¡14.0 9.7¡7.7 0.192a
CSF spread
Yes 38 (86.4%) 7 (100%) 10 (100%) 0.496b
No 6 (13.6%) 0 0
Overall survival (mo) 85.5¡9.9 123.4¡27.0 27.7¡11.7 0.002c
Progression-free
survival (mo) 56.6¡7.6 79.5¡18.0 15.1¡8.6 0.004c
Nuclear b-catenin
negative 31 (70.5%) 6 (85.7%) 7 (70.0%) 0.810b
positive 13 (29.5%) 1 (14.3%) 3 (30.0%)
CTNNB1 mutation
negative 36 (81.8%) 6 (85.7%) 8 (80.0%) 0.496b
positive 8 (18.2%) 1 (14.3%) 2 (20.0%)
Total 44 (72.1%) 7 (11.5%) 10 (16.4%)
For age, overall survival and progression-free survival, mean ¡ SD; mo, months. aKruskal Wallis; bFisher’s exact test; cLog rank test.
FIGURE 1 - b-catenin IHC findings in three representative
medulloblastoma cases. Large-cell variant presenting anaplastic
cells in HE (A, 200x), with the majority of cells presenting positive
cytoplasmic b-catenin reactions but few cell showing positive
nuclear reactions (B, 400x). Large-cell variant with abundant
clear cells in HE (C, 400x) and several positive nuclei intermingled
with a small number of cells presenting a negative cytoplasmic
reaction (D, 600x). Extensive nodularity variant presenting an
islet of positive cells (E, 40x) with strong nuclear reactivity but
lower cytoplasmic reactivity (F, 600x).
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type. Furthermore, there was no correlation between
CTNNB1 mutation status and CSF tumor cell dissemination,
as only one out of four patients with dissemination
presented mutation.
We also analyzed CTNNB1, APC, AXIN1 and WNT1
mRNA expression levels by QT-PCR in 41 medulloblastoma
cases. WNT1 expression could not be detected in most of the
cases, and the data are not presented here. However, the
expression levels of CTNNB1, APC and AXIN1 were
analyzed and compared to a non-tumorous cerebellum
pool. The medulloblastoma samples presented a higher
CTNNB1 expression in most cases as compared to normal
cerebellum tissue (range 0.02-6.76, median value 1.55).
Furthermore, eighteen cases (43.9%) presented overexpres-
sion of CTNNB1. In contrast, APC (range 1.22-40.57, median
value 5.40) and AXIN1 (range 0.18-3.04, median value 0.89)
expression levels presented a wide range of variation. A
total of 14 cases (34.1%) presented APC overexpression,
while AXIN1 overexpression was detected in 16 cases
(39.0%).
We next carried out a Spearman’s Rho analysis of the
relative expression values for CTNNB1, AXIN1 and APC,
although no significant correlation was found. Moreover,
the overexpression status of each gene did not correlate with
the age at diagnosis, gender, CTNNB1 mutation status, b-
catenin nuclear staining, localization of the tumor, dissemi-
nation or overall and progression-free survival time.
We also analyzed the relative expression of these three
genes and their relation to the histological classification of
the medulloblastomas. CTNNB1 presented differences in
relative expression between the large-cell and classic
variants (p,0.05) and also between the large-cell and
desmoplastic/extensive nodularity variants (p,0.0005),
whereas the APC and AXIN1 relative expression levels
did not present differences among the three medulloblas-
toma groups analyzed (Figure 2).
& DISCUSSION
The association between the canonical Wnt pathway and
medulloblastoma has been explored ever since the identi-
fication of mutations in tumor suppressor genes (25-27).
Subsequently, other proteins related to this pathway have
also been studied to evaluate their participation in sporadic
medulloblastomas. In the present work, we evaluated
protein expression (by immunohistochemistry) and genes
(mutation status and expression levels) involved in the Wnt
signaling pathway in a series of 61 medulloblastoma cases.
When we analyzed the survival time according to the
histological type of the medulloblastoma, patients with
large-cell variant tumors had a significantly poorer outcome
than did patients with other variants, corroborating pre-
viously described findings (4,9,28).
Interestingly, when the expression level of genes involved
in the Wnt signaling pathway was examined, no expression
or very low WNT1 transcript levels were detected. These
results are in accordance to the very low frequency (,1%) of
WNT1 expression described by Yokota et al. (29), and these
results also corroborate the role of other members of the
Wnt protein family in medulloblastomas. In contrast, the
downstream targets CTNNB1, APC and AXIN1 were
overexpressed in 43.9%, 34.1% and 39.0%, respectively, of
medulloblastoma cases in the present series. Of note, the
large-cell medulloblastoma variant presented significantly
lower expression levels of CTNNB1 than the other variants.
These findings suggest that the Wnt medulloblastoma
subgroup rarely contains the large-cell variant, and these
results are similar to a recent consensus concerning
medulloblastoma molecular subclassification (9,10).
Cytoplasmic b-catenin immunoreactivity was demonstrated
in all cases, which is in accordance with previous studies
(25,30,31). However, these results were independent of
CTNNB1 expression level or mutational status, which
suggests that b-catenin expression might be regulated by
other pathway proteins, such as ERBB receptors or SUFU
protein. ERBB1/2 receptors interact directly with b-catenin,
leading to its phosphorylation and consequent cytoplasmic
level increase (32), whereas SUFU acts as a negative
regulator of the Wnt pathway by reducing b-catenin in the
nucleus via exporting it into the cytoplasm for degradation
(26,33). Furthermore, b-catenin binds to FAM, a deubiqui-
tinating enzyme also known as USP9X (ubiquitin specific
peptidase 9, X-linked), which inhibits the degradation of
FIGURE 2 - Relative expression levels of the CTNNB1, AXIN1 and
APC genes in medulloblastoma cases according to histological
classification. * p,0.05; *** p,0.0005.
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b-catenin, leading to its accumulation in the cytoplasm
(34,35). Additionally, APC and AXIN1 can shuttle b-catenin
from the nucleus to the cytoplasm (36,37).
In contrast to the cytoplasmic reactivity observed for b-
catenin in all cases, nuclear staining of the protein was
observed in 17 out of 61 cases (27.9%). One potential
explanation for b-catenin nuclear accumulation relates to
the form of the protein that is generated by the mutation,
which predominates in the nucleus (25). Additionally,
CTNNB1 was found to be overexpressed in 43.9% of the
medulloblastoma cases analyzed. However, neither
CTNNB1 mutation status nor gene expression level could
be correlated to protein expression or the nuclear location of
b-catenin.
The upregulation of b-catenin observed in our study via
gene and protein expression analyses may also have been
influenced by the oncoprotein MUC1, which interacts
directly with b-catenin to block GSK3b-mediated phosphor-
ylation and consequent b-catenin degradation (38).
The overall mutation rate identified for CTNNB1 (18.0%)
in the present series was similar to previously reported
results from other studies (39-41). In the present study, all
the studied cases presented missense heterozygotic
CTNNB1 mutations in highly conserved serine residues
that are phosphorylation sites for GSK3b and required for
the degradation of b-catenin or at codons that code for
amino acids flanking those serine residues. Alteration in one
allele is sufficient to induce b-catenin nuclear translocation,
which triggers its oncogenic role; therefore, all mutations
can be considered dominant activating mutations (17-18).
However, the present results confirm that CTNNB1 muta-
tional status might not be the only factor determining the
trafficking of b-catenin within the cell. As described
previously, accumulation of this protein has also been
observed without CTNNB1 mutation (29) and in the
presence of mutations in other genes downstream in the
Wnt pathway, such as APC and AXIN1. In fact, APC and
AXIN1 are important for the export of b-catenin from the
nucleus to the cytoplasm (36,37), and nuclear accumulation
of b-catenin has been observed in colorectal cancers with
APC mutations (37,42,43). A similar mechanism for b-
catenin nuclear accumulation might also be expected in
medulloblastomas because APC mutations have been
described in 4.3% of cases of this type of tumor (44).
AXIN1 mutations have also been reported in 5% of
medulloblastoma cases (45), and such mutations might also
lead to b-catenin nuclear accumulation. Furthermore, the
post-APC knockdown accumulation of b-catenin in the
nucleus observed in a medulloblastoma cell line provides
additional in vitro evidence of the mechanisms underlying
alterations in b-catenin trafficking (46).
Additionally, epigenetic silencing of genes coding for the
secreted frizzled-related protein (SFRP1, SFRP2 and SFRP3)
family members has been described as an additional
mechanism that may activate the Wnt signaling pathway
in medulloblastomas (47). Furthermore, the SFRP family
members code for proteins that can limit Wnt signaling, as
these soluble proteins bind to Wnt ligands and sequester
them from the frizzled receptors, which are the serpentine
receptors responsible for binding to Wnt proteins at the
plasma membrane (48).
Few previous studies have focused on the expression
level of b-catenin transcripts in medulloblastomas or on the
expression of genes coding for the proteins involved in the
Wnt signaling pathway. Thus, this study is the first to
demonstrate the relative mRNA expression of genes
involved in the Wnt pathway in medulloblastomas using
QT-PCR. When we analyzed the expression levels of
CTNNB1, AXIN1 and APC according to the medulloblas-
toma histological type, CTNNB1 presented lower relative
gene expression levels in large-cell variant tumors than in
the classic or desmoplastic/extensive nodularity type
tumors. However, Wnt signaling activation has been
described most frequently in classic medulloblastomas
(4,6), which suggests that these data should be further
evaluated with a larger number of samples because
desmoplastic, extensive nodularity and large-cell medullo-
blastomas are not as common as classic medulloblastoma
variant tumors. The expression levels of CTNNB1, AXIN1
and APC did not correlate with the b-catenin mutation
status, which corroborates previous gene expression micro-
array analyses (49). Furthermore, the analyzed gene profiles
were not significantly associated with tumor cell dissemina-
tion or the progression-free and overall survival times.
The results of our study suggest that molecular pathways
other than the Wnt pathway are involved in medulloblas-
toma formation, such as the Sonic hedgehog signaling
pathway (SHH subgroup) and the Notch pathway, as well
as additional cytogenetic aberrations (5-8). In summary, we
demonstrated that only a small subset of medulloblastomas
carry the CTNNB1 gene mutation that leads to nuclear
accumulation of b-catenin. Thus, components of the Wnt
signaling pathway as well as other signaling pathways play
important roles in the genetic abnormalities underlying
medulloblastomas. The present findings confirm the impor-
tance of the Wnt pathway in classic, desmoplastic and
extensive nodularity tumor variants but not in the large-cell
medulloblastoma variant.
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